Market capitalization | $1.17b |
Enterprise Value | $956.34m |
P/E (TTM) P/E ratio | 23.72 |
EV/FCF (TTM) EV/FCF | 5.96 |
EV/Sales (TTM) EV/Sales | 0.84 |
P/S ratio (TTM) P/S ratio | 1.03 |
P/B ratio (TTM) P/B ratio | 2.80 |
Revenue growth (TTM) Revenue growth | 10.24% |
Revenue (TTM) Revenue | $1.14b |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
11 Analysts have issued a Progyny Inc forecast:
11 Analysts have issued a Progyny Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,139 1,139 |
10%
10%
|
|
Gross Profit | 247 247 |
9%
9%
|
|
EBITDA | 68 68 |
27%
27%
|
EBIT (Operating Income) EBIT | 65 65 |
27%
27%
|
Net Profit | 57 57 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Progyny, Inc. is a medical device company. It engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. The firm operates through the following segments: medical device and fertility benefits solution. The company's services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Head office | United States |
CEO | Peter Anevski |
Employees | 566 |
Founded | 2008 |
Website | www.progyny.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.